Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD.
Discussion: The study highlights the interaction and relevance of personal real-time monitoring of respiratory symptoms, physical activity and rescue medication in patients with COPD. Additionally, visual displays of longitudinal data may be helpful for disease management to help drive conversations between patients and caregivers and for risk-based monitoring in clinical trials. PMID: 30956796 [PubMed]
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Long-acting Muscarinic Antagonists (LAMA); Drug: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA) Sponsor: Boehringer Ingelheim Not yet recruiting
Condition: COPD Intervention: Sponsor: University Hospital, Brest Not yet recruiting
Publication date: Available online 19 November 2019Source: Journal of PhysiotherapyAuthor(s): Tristan Bonnevie, Mark Elkins
CONCLUSIONS: Common comorbidities modify the association of frailty with postoperative survival; however, this effect was only apparent when analyses accounted for effect modification on the absolute risk difference, as opposed to relative scale. While the relative scale is more commonly used in biomedical research, smaller effects may be easier to detect on the risk difference scale. The concurrent presence of dementia, COPD, and HF with frailty were all associated with excess mortality on the absolute risk difference scale. PMID: 31743191 [PubMed - in process]
The role of Kv11.1 potassium channels in the lung is unclear. Shults et al (Am J Pathol, AJPA_2019_212) studied the expression of Kv11.1 in healthy human and rat lung tissues and in humans with chronic obstructive pulmonary disease (COPD)-associated pulmonary hypertension (PH) and rats with pulmonary arterial hypertension (PAH). Kv11.1 channels are amply expressed in and confined to the large pulmonary arteries (PAs) of healthy lung tissues. This expression increases in human lungs affected by COPD-associated PH and in mouse lungs with PAH, with detectable expression in small PAs.
Severe obstructive lung disease, which encompasses asthma, chronic obstructive pulmonary disease (COPD) or features of both, remains a considerable global health problem and burden on healthcare resources. However, the clinical definitions of severe asthma and COPD do not reflect the heterogeneity within these diagnoses or the potential for overlap between them, which may lead to inappropriate treatment decisions. Furthermore, most studies exclude patients with diagnoses of both asthma and COPD. Clinical definitions can influence clinical trial design and are both influenced by, and influence, regulatory indications and tr...
Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pulmonary disease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment. We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks. Patients used an electronic diary to capture exacerbations. The primary endpoint was time from randomisation to the first event-based exacerbation. Secondary endpoints included change in the nature of the exacerbation as defined by the Anthonisen criteria. Sa...
α1-Antitrypsin deficiency (AATD) is a genetic disorder that predisposes to the development of early pulmonary emphysema, especially in smokers. Episodes of exacerbations are frequent in patients with emphysema due to AATD and are associated with a deficient antiprotease screen in the airways compared with that of non-deficient COPD patients . As a consequence, exacerbations have great impact on the evolution of the lung disease in AATD, measured in terms of decline in gas transfer , in health status [2, 3], and in lung function over time [4, 5].
Condition: COPD Exacerbation Interventions: Other: Conventional Chest Physiotherapy; Other: Conventional Chest Physiotherapy+Incentive Spirometer Sponsor: Bezmialem Vakif University Not yet recruiting
Condition: Chronic Obstructive Pulmonary Disease (COPD) Intervention: Device: Reveal LINQ Sponsor: Medtronic Cardiac Rhythm and Heart Failure Not yet recruiting